A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2016-11-16
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving panobinostat together with lenalidomide works in
treating patients with relapsed or refractory Hodgkin lymphoma. Panobinostat may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological
therapies, such as lenalidomide, may stimulate the immune system in different ways and stop
cancer cells from growing. Giving panobinostat together with lenalidomide may be an effective
treatment for Hodgkin lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Kristie Blum Ohio State University Comprehensive Cancer Center